论文部分内容阅读
应用宝泰PM免疫调节剂治疗60例常年性变应性鼻炎，根据治疗前后病情分级的改善和变应原鼻粘膜激发试验评定，有效率分别为90％和86．7％。治疗前后血清及鼻分泌物中广谱凝集抗体效价、特异性IgG和SIgA抗体阳性检出率及抗体满度均有不同程度改变，其中血清绿脓杯自MSHA菌毛株凝集抗体液度比治疗前增加4～64倍，鼻分泌物中治疗前后绿脓杆菌菌毛株凝集抗体阳性人数检出率有非常显著性差异（P＜0．005）；治疗后血清中变形杆菌、大肠杆菌、绿脓杆菌菌毛株特异性IgG荧光抗体滴度有一定程度增加，鼻分泌物中绿脓杆菌菌毛株特异性SIgA荧光抗体治疗前后阳性人数检出卓有高度显著性差异（P＜0．005）。本治疗机理是采用低毒、广谱、较强免疫原性的绿脓杆菌MSHA菌毛株菌苗，进行全身免疫治疗，刺激机体产生高效价、跨菌属抗体，并结合其他免疫调节作用达到治疗目的。
Baotai PM immunomodulator treatment of 60 cases of perennial allergic rhinitis, according to the improvement of the condition before and after treatment and allergen nasal mucosal challenge test evaluation, the effective rates were 90% and 86.7%. Serum and nasal secretions before and after treatment in a wide range of agglutinating antibody titers, specific IgG and SIgA antibody positive detection rate and antibody fullness have varying degrees of change, in which the serum pus cup since MSHA pili agglutination antibody liquid ratio Pre-treatment increased 4 to 64 times, before and after treatment of nasal secretions of Pseudomonas aeruginosa strains agglutinating antibody positive number of detection rate was significantly different (P <0.005); after treatment, Proteus, Escherichia coli, Pseudomonas aeruginosa strains specific IgG fluorescent antibody titers increased to some extent, the nasal secretions in the Pseudomonas aeruginosa hair strain-specific SIgA fluorescent antibody detection before and after treatment of positive numbers were highly significant difference (P <0. 005). The treatment mechanism is the use of low toxicity, broad-spectrum, strong immunogenicity of Pseudomonas aeruginosa MSHA fimbriae vaccine for systemic immunotherapy to stimulate the body to produce high titer, cross-bacteria antibodies, combined with other immunomodulatory effects The purpose of treatment.